Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions

Transfusion

Volumn 59, Issue 4, 2019, Pages 1291-1299

  Kacker, Seema ^a   Bloch, Evan M ^a   Ness, Paul M ^a   Gehrie, Eric A ^a   Marshall, Christi E ^a   Lokhandwala, Parvez M ^a   Tobian, Aaron A R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BLOOD EXAMINATION; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EXPIRATION DATE; HEALTH CARE COST; HUMAN; HUMAN CELL; INFECTION CONTROL; INFECTION RISK; INTERMETHOD COMPARISON; MONTE CARLO METHOD; NONHUMAN; POINT OF RELEASE TESTING; RISK REDUCTION; SECONDARY BACTERIAL CULTURE; SENSITIVITY AND SPECIFICITY; SEPSIS; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS; COST; DISINFECTION; ECONOMIC MODEL; ECONOMICS; MICROBIOLOGY; THROMBOCYTE;

BLOOD PLATELETS; COSTS AND COST ANALYSIS; DISINFECTION; HUMANS; MODELS, ECONOMIC; MONTE CARLO METHOD; PLATELET TRANSFUSION;

EID: 85059769247     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15139     Document Type: Article

References (39)

1. FDA-CBER. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. March 2016 [cited 2018 August 1]. Available from: https://www.fda.gov/downloads/Guidances/Blood/UCM425952.pdf. [Online].
2. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001;41:1493-9.
3. Yomtovian R. Bacterial contamination of blood: lessons from the past and road map for the future. Transfusion 2004;44:450-60.
4. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015;162:205-13.
5. Ramirez-Arcos S, Difranco C, McIntyre T, et al. Residual risk of bacterial contamination of platelets: six years of experience with sterility testing. Transfusion 2017;57:2174-81.
6. Morrow JF, Braine HG, Kickler TS, et al. Septic reactions to platelet transfusions: a persistent problem. JAMA 1991;266:555-8.
7. Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007;131:702-70.
8. Arefian H, Heublein S, Scherag A, et al. Hospital-related cost of sepsis: a systematic review. J Infect 2017;74:107-17.
9. Aubuchon JP, Cooper LK, Leach MF, et al. Experience with universal bacterial culturing to detect contamination of apheresis platelet units in a hospital transfusion service. Transfusion 2002;42:855-61.
10. Benjamin RJ, Wagner SJ. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion 2007;47:1381-9.
11. Murphy WGW, Foley MM, Doherty CC, et al. Screenng platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008;95:13-9.
12. Benjamin R. Transfusion-related sepsis: a silent epidemic. Blood 2016;127:380-1.
13. Dumont LJ, Kleinman S, Murphy JR, et al. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010;50:589-99.
14. Fatalities reported to FDA following blood collection and transfusion annual summary for fiscal year 2016 [cited 2018 August 1]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM598243.pdf. [Online]
15. Brecher ME, Blajchman MA, Yomtovian R, et al. Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future. Transfusion 2013;53:221-31.
16. McDonald CP, Roy A, Mahajan P, et al. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion. Vox Sang 2004;86:178-82.
17. de Korte DM, Marcelis JH. Platelet concentrates: reducing the risk of transfusion-transmitted bacterial infections. Int J Clin Transfus Med 2014;2:9.
18. Liumbruno GM, Catalano L, Piccinini V, et al. Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components. Blood Transfus 2009;7:86-93.
19. Jenkins C, Ramirez-Arcos S, Goldman M, et al. Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk. Transfusion 2011;51:2555-65.
20. The INTERCEPT blood system for platelets package insert. Cerus Corporation; 2018 [cited 2018 August 1]. Available from: https://interceptusa.com/images/resources/Package_Inserts/INTERCEPT_Blood System_INT2530B_DS_Package_Insert_May-2018.pdf.
21. Mirasol pathogen reduction technology (PRT) system. 2018 [cited 2018 August 1]. Available from: https://www.terumobct.com/mirasol.
22. Bloch EM, Marshall CE, Boyd JS, et al. Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions. Transfusion 2018;58:1647-53.
23. Hong H, Xiao W, Lazarus H, et al. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood 2016;127:496-502.
24. Erony SM, Marshall CE, Gehrie EA, et al. The epidemiology of bacterial culture–positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016. Transfusion 2018;58:1933-9.
25. Benjamin RJ, Blood Products Advisory Committee. [cited 2012 September 21]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM325690.pdf. [Online]
26. Braine HG, Kickler TS, Charache P, et al. Bacterial sepsis secondary to platelet transfusion: an adverse effect of extended storage at room temperature. Transfusion 1986;26:391-3.
27. Schmidt M, Hourfar MK, Sireis W, et al. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains. Transfusion 2015;55:2104-12.
28. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104:1534-40.
29. Li JW, Brecher ME, Jacobson JL, et al. Addressing the risk of bacterial contamination in platelets: a hospital economic perspective. Transfusion 2017;57:2321-8.
30. Verax. Platelet PGD test [package insert]. 2009 [cited 2018 August 1]. Available from: https://www.veraxbiomedical.com//wp-content/uploads/2018/01/US_Platelet_PGD_Test.pdf.
31. Ellingson KD, Sapiano MRP, Haass KA, et al. Continued decline in blood collection and transfusion in the United States–2015. Transfusion 2017;57:1588-98.
32. McCullough J, Goldfinger D, Gorlin J, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion 2015;55:2312-20.
33. Riley W, Smalley B, Pulkrabek S, et al. Using lean techniques to define the platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion strategies. Transfusion 2012;52:1957-67.
34. Ho V, Metcalfe L, Dark C, et al. Comparing utilization and costs of care in freestanding emergency departments, hospital emergency departments, and urgent care centers. Ann Emerg Med 2017;70:846-57.
35. Vauthrin M, Greene M, Weinstein R. Verax platelet PGD test workflow strategy. Transfusion 2016;56:198A.
36. Kaufman RM. Platelets: testing, dosing and the storage lesion - recent advances. Hematology 2006;2006:492-6.
37. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a consensus conference: pathogen inactivation – making decisions about new technologies. Transfus Med Rev 2008;22:1-34.
38. Centers for Medicare & Medicaid Services. Clin lab fee schedule. April 2018 [cited 2018 August 1]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files.html.
39. FDA-CBER. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. December 2018 [cited 2019 January 4]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM627407.pdf. [Online].